In an intensive pharmacokinetic study of adalimumab (ADA) in Crohn's disease (CD), trough drug levels were significantly higher in syringe compared with pen users.
Conclusions: Drug delivery device does not appear to significantly affect ADA drug levels. Nevertheless, given site-specific differences between pen and syringe, further prospective controlled studies which include patient administration training are warranted. Background: Mayo endoscopic score (MES) is widely used in the evaluation of ulcerative colitis (UC) activity. Both MES of 0 and 1 are considered as mucosal healing. However, recent study reported that UC patients with the MES of 1 had the worse outcome than those with the MES of 0. Furthermore, it is not clear whether therapeutic intervention for UC patients with the MES of 1 alters clinical outcome. Therefore, we aimed to investigate the efficacy of therapeutic intervention for UC patients with the MES of 1 in this study. Methods: UC patients who had the MES of 1 and the partial Mayo score (pMayo) ≤2 were included in this study. Among them, participants who did not undergo CS after 1 year were excluded. Patients were followed up within 1 year after the initial colonoscopy. Risk factors for relapse (defined as clinical relapse or endoscopic aggravation) were assessed. Clinical relapse was defined as the case that needed any therapeutic intervention for 1 year after first CS. Endoscopic aggravation was evaluated at 1 year after enrollment. Results: Among 1523 UC patients who underwent CS, 235 patients had MES of 1 with clinical remission (pMayo ≤2) at the enrollment. Even among patients with the MES of 1, 52 (22.1%) patients received additional treatment according to the initial endoscopic findings (the addition of topical treatment 43, 5-ASA escalation 17, thiopurine escalation 4, and the addition of corticosteroid 1). Univariate analysis indicated that therapeutic intervention just after first CS (p = 0.004), UCEIS vascular pattern score (p = 0.012), UCEIS erosion/ ulcer score (p = 0.017), pMayo (p = 0.033), and CRP (p = 0.049) were risk factors for clinical relapse. Multivariable analysis indicated that non-therapeutic intervention (p = 0.001, OR 5.36, 95% CI: 2.18-13.1) and higher UCEIS vascular pattern score (p = 0.002, OR 3.18, 95% CI: 1.53-6.57) were the risk factors for relapse. Relapse rate in patients with therapeutic intervention (30.8%) was significantly lower than that patients without therapeutic intervention (57.4%) during the follow-up period (p = 0.004). Conclusions: Therapeutic intervention for UC patients with the MES of 1 might prevented disease relapse. Among patients with the MES of 1, the items of UCEIS vascular pattern is also associated with relapse for UC.
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